Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2011 April;52(2) > The Journal of Cardiovascular Surgery 2011 April;52(2):225-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

REVIEWS  DRUG-ELUTING TECHNOLOGIES: WHERE ARE WE 

The Journal of Cardiovascular Surgery 2011 April;52(2):225-9

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents above the knee

Minar E.

Department of Angiology, Medical University Vienna, Vienna, Austria


PDF


There are only very few trials concerning use of drug-eluting stents (DES) in the femoropopliteal segment. While earlier trials using a sirolimus-eluting polymer-coated stent and an everolimus-eluting stent failed to demonstrate improved mid-term patency compared with a bare-metal stent, the recently presented ‑ however still unpublished – data with the Zilver PTX stent using a polymer-free paclitaxel coating are very promising. Before we can make definite conclusions and recommendations, we have to see longer-term follow-up data. A potential future improvement of local drug application for the necessary time span without the disadvantages of permanent stent implantation can be expected by the development of completely bioabsorbable DES.

top of page